Vaxcyte
$58.5
25
+$0.39+0.67% Wednesday 20:00
Statistics
Day High
59.69
Day Low
57.48
52W High
65
52W Low
27.66
Volume
2,674,678
Avg. Volume
1,400,083
Mkt Cap
8.42B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
11MayExpected
Expected EPS
-1.741111
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-1.53BNet Income
Analyst Ratings
$105.00Average Price Target
The highest estimate is 116.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow PCVX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap140.15B
Merck
MRK
Mkt Cap214.76B
GSK
GSK
Mkt Cap94.51B
Sanofi
SNY
Mkt Cap124.45B
Novavax
NVAX
Mkt Cap1.36B
BioNTech
BNTX
Mkt Cap24.99B
Johnson & Johnson
JNJ
Mkt Cap455.04B
Astrazeneca
AZN
Mkt Cap256.58B
About
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Show more...
CEO
Mr. Grant E. Pickering M.B.A.
Employees
414
Country
US
ISIN
US92243G1085
Listings
0 Comments
Share your thoughts
FAQ
What is Vaxcyte stock price today?▼
The current price of PCVX is $58.5 USD — it has increased by +0.67% in the past 24 hours. Watch Vaxcyte stock price performance more closely on the chart.
What is Vaxcyte stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Vaxcyte stocks are traded under the ticker PCVX.
Is Vaxcyte stock price growing?▼
PCVX stock has risen by +6.93% compared to the previous week, the month change is a -5.61% fall, over the last year Vaxcyte has showed a +73.64% increase.
What is Vaxcyte market cap?▼
Today Vaxcyte has the market capitalization of 8.42B
When is the next Vaxcyte earnings date?▼
Vaxcyte is going to release the next earnings report on May 11, 2026.
What were Vaxcyte earnings last quarter?▼
PCVX earnings for the last quarter are -1.81 USD per share, whereas the estimation was -1.53 USD resulting in a -18.32% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Vaxcyte revenue for the last year?▼
Vaxcyte revenue for the last year amounts to 0 USD.
What is Vaxcyte net income for the last year?▼
PCVX net income for the last year is -1.53B USD.
How many employees does Vaxcyte have?▼
As of April 02, 2026, the company has 414 employees.
In which sector is Vaxcyte located?▼
Vaxcyte operates in the Health Care sector.
When did Vaxcyte complete a stock split?▼
Vaxcyte has not had any recent stock splits.
Where is Vaxcyte headquartered?▼
Vaxcyte is headquartered in San Carlos, US.